Total Payments
$519,302
2024 Payments
$70,476
Companies
63
Transactions
1,322
Medicare Patients
6,697
Medicare Billing
$4.7M
Payment Breakdown by Category
Other$400,945 (77.2%)
Consulting$76,515 (14.7%)
Food & Beverage$22,896 (4.4%)
Travel$16,491 (3.2%)
Research$2,288 (0.4%)
Education$166.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $397,895 | 204 | 76.6% |
| Consulting Fee | $76,515 | 30 | 14.7% |
| Food and Beverage | $22,896 | 1,002 | 4.4% |
| Travel and Lodging | $16,491 | 70 | 3.2% |
| Honoraria | $3,050 | 2 | 0.6% |
| Unspecified | $2,288 | 10 | 0.4% |
| Education | $166.67 | 4 | 0.0% |
Payments by Type
General
$517,014
1,312 transactions
Research
$2,288
4 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $257,649 | 290 | $0 (2024) |
| Allergan, Inc. | $208,019 | 303 | $0 (2021) |
| Biohaven Pharmaceuticals, Inc. | $16,417 | 19 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $14,912 | 26 | $0 (2022) |
| Promius Pharma LLC | $5,564 | 24 | $0 (2019) |
| Lundbeck LLC | $3,457 | 35 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $2,076 | 36 | $0 (2023) |
| Eli Lilly and Company | $1,576 | 2 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $890.74 | 55 | $0 (2022) |
| Genentech USA, Inc. | $816.25 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,476 | 147 | ABBVIE INC. ($67,299) |
| 2023 | $36,935 | 106 | ABBVIE INC. ($35,909) |
| 2022 | $73,978 | 195 | ABBVIE INC. ($56,964) |
| 2021 | $129,483 | 238 | AbbVie Inc. ($97,477) |
| 2020 | $95,741 | 218 | Allergan, Inc. ($91,716) |
| 2019 | $32,302 | 112 | Allergan Inc. ($30,952) |
| 2018 | $21,270 | 154 | Allergan Inc. ($14,899) |
| 2017 | $59,117 | 152 | Allergan Inc. ($57,424) |
All Payment Transactions
1,322 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Neurology | ||||||
| 12/13/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $28.34 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/11/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $22.43 | General |
| Category: Narcoplepsy | ||||||
| 12/11/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $1.62 | General |
| Category: Narcoplepsy | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $31.89 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Immunology | ||||||
| 11/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | ABBVIE INC. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $64.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: PAIN | ||||||
| 10/31/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Lundbeck LLC | VYEPTI (Biological) | Honoraria | Cash or cash equivalent | $1,860.00 | General |
| Category: NEUROLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | Lilly USA, LLC | EMGALITY (Drug), AMYVID, REYVOW | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: EPILEPSY | ||||||
| 10/17/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $0.01 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE | Eli Lilly and Company | $1,576 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,825 | 211,464 | $6.5M | $1.4M |
| 2022 | 22 | 1,768 | 190,605 | $5.9M | $1.3M |
| 2021 | 21 | 1,570 | 163,755 | $5.0M | $1.1M |
| 2020 | 23 | 1,534 | 140,717 | $3.9M | $854,451 |
Total Patients
6,697
Total Services
706,541
Medicare Billing
$4.7M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 285 | 157,610 | $3.2M | $747,922 | 23.7% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 50 | 35,000 | $2.3M | $471,084 | 20.7% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 286 | 940 | $408,900 | $109,960 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 299 | 464 | $153,450 | $41,698 | 27.2% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 54 | 58 | $88,740 | $9,933 | 11.2% |
| 64400 | Injection of anesthetic agent and/or steroid into face nerve | Office | 2023 | 35 | 75 | $43,680 | $9,144 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 102 | 128 | $28,800 | $8,695 | 30.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $28,350 | $7,814 | 27.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 57 | 150 | $32,250 | $7,692 | 23.9% |
| 70549 | Mri scan of blood vessels of neck before and after contrast | Office | 2023 | 26 | 28 | $54,040 | $6,087 | 11.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $23,500 | $5,475 | 23.3% |
| 64505 | Injection of anesthetic agent, trigeminal nerve bundle | Office | 2023 | 16 | 38 | $14,402 | $3,964 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 26 | $11,440 | $3,522 | 30.8% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2023 | 34 | 53 | $18,620 | $3,158 | 17.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 131 | 306 | $24,480 | $3,153 | 12.9% |
| 70544 | Mri scan of blood vessels of head without contrast | Office | 2023 | 32 | 35 | $42,875 | $2,710 | 6.3% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 34 | 53 | $23,715 | $2,173 | 9.2% |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | Office | 2023 | 70 | 15,089 | $9,808 | $1,715 | 17.5% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 22 | 48 | $9,360 | $1,175 | 12.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $3,630 | $862.23 | 23.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 12 | 35 | $3,325 | $810.28 | 24.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 18 | $2,430 | $808.20 | 33.3% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 74 | 404 | $2,020 | $164.57 | 8.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 54 | 740 | $3,700 | $69.27 | 1.9% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 15 | 63 | $315.00 | $4.70 | 1.5% |
About Dr. Steven Herzog, M.D
Dr. Steven Herzog, M.D is a Neurology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972579449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Herzog, M.D has received a total of $519,302 in payments from pharmaceutical and medical device companies, with $70,476 received in 2024. These payments were reported across 1,322 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($397,895).
As a Medicare-enrolled provider, Herzog has provided services to 6,697 Medicare beneficiaries, totaling 706,541 services with total Medicare billing of $4.7M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Dallas, TX
- Active Since 02/24/2006
- Last Updated 09/02/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1972579449
Products in Payments
- UBRELVY (Drug) $245,314
- BOTOX (Biological) $110,010
- QULIPTA (Drug) $74,313
- NURTEC ODT (Drug) $31,433
- BOTOX (Drug) $30,760
- Zembrace (Drug) $5,467
- VYEPTI (Biological) $3,430
- AJOVY (Biological) $1,607
- BOTOX CHRONIC MIGRAINE (Drug) $1,035
- APTIOM (Drug) $715.40
- OCREVUS (Biological) $632.42
- Aimovig (Biological) $545.40
- Briviact (Drug) $411.90
- EMGALITY (Drug) $372.30
- TROKENDI XR (Drug) $300.42
- KESIMPTA (Drug) $298.00
- VYVGART (Drug) $236.79
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $233.55
- Xeomin (Biological) $225.28
- TYSABRI (Biological) $210.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Dallas
Nirav Pavasia, M.d, M.D
Neurology — Payments: $1.3M
Neurology $1.3M
Benjamin Greenberg, Md, MD
Neurology — Payments: $691,893
Neurology $691,893
Waleed El-Feky, M.d, M.D
Neurology — Payments: $469,716
Neurology $469,716
Mark Alberts, Md, MD
Neurology — Payments: $417,917
Neurology $417,917
Adnan Subei, D.o, D.O
Neurology — Payments: $274,043
Neurology $274,043
Shanan Munoz, M.d, M.D
Neurology — Payments: $268,254
Neurology $268,254